» Articles » PMID: 36005134

and Genes Expression Level in Adult Acute Lymphoblastic Leukemia-A Case Control Study

Overview
Publisher MDPI
Specialty Molecular Biology
Date 2022 Aug 25
PMID 36005134
Authors
Affiliations
Soon will be listed here.
Abstract

The genetic factors of adult acute lymphoblastic leukemia (ALL) development are only partially understood. The Runt-Related Transcription Factor () gene family play a crucial role in hematological malignancies, serving both a tumor suppressor and promoter function. The aim of this study was the assessment of relative and genes expression level among adult ALL cases and a geographically and ethnically matched control group. The relative and genes expression level was assessed by qPCR. The investigated group comprised 60 adult patients newly diagnosed with ALL. The obtained results were compared with a group of 40 healthy individuals, as well as clinical and hematological parameters of patients, and submitted for statistical analysis. ALL patients tend to have significantly higher gene expression level compared with controls. This observation is also true for risk group stratification where high-risk (HR) patients presented higher levels of . A higher transcript level correlates with greater leukocytosis while expression is reduced in Philadelphia chromosome bearers. The conducted study sustains the hypothesis that both a reduction and increase in the transcript level of family genes may be involved in leukemia pathogenesis, although their interaction is complex. In this context, overexpression of the gene in adult ALL cases in particular seems interesting. Obtained results should be interpreted with caution. Further analysis in this research field is needed.

Citing Articles

Editorial for the Special Issue 'Molecular Mechanisms of Leukemia'.

An J, Ko M Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852129 PMC: 11763483. DOI: 10.3390/cimb47010014.

References
1.
Mevel R, Draper J, Lie-A-Ling M, Kouskoff V, Lacaud G . RUNX transcription factors: orchestrators of development. Development. 2019; 146(17). DOI: 10.1242/dev.148296. View

2.
Medinger M, Lengerke C, Passweg J . Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer Genomics Proteomics. 2016; 13(5):317-29. PMC: 5070622. View

3.
Grossmann V, Kern W, Harbich S, Alpermann T, Jeromin S, Schnittger S . Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica. 2011; 96(12):1874-7. PMC: 3232273. DOI: 10.3324/haematol.2011.043919. View

4.
Sakurai H, Harada Y, Ogata Y, Kagiyama Y, Shingai N, Doki N . Overexpression of short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms. Blood Adv. 2018; 1(18):1382-1386. PMC: 5727847. DOI: 10.1182/bloodadvances.2016002725. View

5.
Fu L, Fu H, Tian L, Xu K, Hu K, Wang J . High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia. Oncotarget. 2016; 7(13):15828-39. PMC: 4941280. DOI: 10.18632/oncotarget.7489. View